# Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

> **NCT01743157** · PHASE1,PHASE2 · COMPLETED · sponsor: **California Pacific Medical Center Research Institute** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Biochemo + bevacizumab then ipilimumab

## Key facts

- **NCT ID:** NCT01743157
- **Lead sponsor:** California Pacific Medical Center Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01743157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01743157, "Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01743157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*